3.Efficacy and safety of vardenafil in difficult-to-treat erectile dysfunction men.
National Journal of Andrology 2006;12(4):377-380
This paper reviewed the efficacy and safety of vardenafil, a highly selective phosphodiesterase type 5 (PDE 5) inhibitor, in men with erectile dysfunction who were difficult to treat. Several large-scale studies indicated vardenafil was effective and safe in the treatment of these difficult-to-treat ED patients, including ED with depression or diabetes, ED after radical retropubic prostatectomy, ED caused by spinal cord injury, and sildenafil nonresponders. Vardenafil provides a rational treatment alternative.
Erectile Dysfunction
;
drug therapy
;
Humans
;
Imidazoles
;
therapeutic use
;
Male
;
Middle Aged
;
Phosphodiesterase Inhibitors
;
therapeutic use
;
Piperazines
;
therapeutic use
;
Sulfones
;
therapeutic use
;
Treatment Outcome
;
Triazines
;
therapeutic use
;
Vardenafil Dihydrochloride
4.Combined therapy with daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b: a case report.
Journal of Southern Medical University 2016;36(8):1163-1164
The combination therapy with daclatasvir and asunaprevir can achieve a high sustained viral response rate against hepatitis C virus (HCV) genotype 1, but so far this regimen has not been reported in the treatment of Chinese patients with chronic hepatitis C (CHC) genotype 1b. Here we report a case of CHC genotype 1b in a 44-year-old female chinese patient who was treated with this regimen for 24 weeks. The patient showed sustained viral response after the treatment and was clinically cured. During the treatment, the patient experienced a transient elevation of serum total bilirubin accompanied by lowered hemoglobin fluctuating between 100 and 110 g/L.
Adult
;
Antiviral Agents
;
therapeutic use
;
Female
;
Genotype
;
Hepacivirus
;
genetics
;
Hepatitis C, Chronic
;
drug therapy
;
Humans
;
Imidazoles
;
therapeutic use
;
Isoquinolines
;
therapeutic use
;
Sulfonamides
;
therapeutic use
5.Application of imiquimod and resiquimod in dermatology.
Acta Academiae Medicinae Sinicae 2006;28(3):445-447
Imiquimod (R-837) and Resiquimod (R-838), two novel small-molecular-weight immune response modifiers, have similar structure. They have anti-virus and anti-tumor activities and can be used as B lymphocyte activators and adjuvants. They are widely used in dermatology to treat virus dermatoses and cutaneous benign or malignant tumors.
Adjuvants, Immunologic
;
therapeutic use
;
Aminoquinolines
;
therapeutic use
;
Antineoplastic Agents
;
therapeutic use
;
Condylomata Acuminata
;
drug therapy
;
Humans
;
Imidazoles
;
therapeutic use
;
Skin Neoplasms
;
drug therapy
6.PDE5 inhibitors for the management of temporary penile erectile dysfunction during treatment with assisted reproductive technology.
Qian-Jin FEI ; Cheng-Shuang PAN ; Xue-Feng HANG
National Journal of Andrology 2013;19(11):991-995
OBJECTIVETo evaluate phosphodiesterase type 5 (PDE5) inhibitors in the management of temporary penile erectile dysfunction (ED) in patients undergoing assisted reproductive technology (ART).
METHODSThis study included 75 male patients that experienced ejaculation failure due to temporary ED during ART treatment. We treated the patients with PDE5 inhibitors sildenafil, tadanafil and vardenafil, and then evaluated the hardness of penile erection using Erection Hardness Score (EHS) and analyzed the end-point efficacy.
RESULTSSildenafil was administered to 28 of the patients, tadanafil to 25, and vardenafil to 22. Of the total number of patients, 61 (81.3%) achieved effective erection, but no significant differences were observed in the rate of effectiveness among the sildenafil (24 cases, 85.7%), tadanafil (20 cases, 80.0%) and vardenafil (17 cases, 77.3%) groups (P > 0.05). After medication, 53 (70.7%) of the patients successfully ejaculated, but there were no remarkable differences in the success rate among the sildenafil (21 cases, 75.0%), tadanafil (17 cases, 68.0%) and vardenafil (15 cases, 68.2%) groups (P > 0.05). Of the 75 patients, 37 received the recommended initial dose and 38 the maximum recommended dose of PDE5 inhibitors, but no significant differences were found in the rate of successful sperm retrieval between the former (28 cases, 75.7%) and the latter group (25 cases, 65.8%) (P > 0.05). Mild adverse events, including transient flush and dizziness, occurred in 5 cases (6.7%).
CONCLUSIONPDE5 inhibitors can help temporary ED patients to achieve penile erection and ejaculation during ART treatment.
Ejaculation ; Erectile Dysfunction ; drug therapy ; Humans ; Imidazoles ; therapeutic use ; Male ; Phosphodiesterase 5 Inhibitors ; therapeutic use ; Piperazines ; therapeutic use ; Purines ; therapeutic use ; Reproductive Techniques, Assisted ; Sildenafil Citrate ; Sulfonamides ; therapeutic use ; Sulfones ; therapeutic use ; Triazines ; therapeutic use ; Vardenafil Dihydrochloride
7.Vardenafil for refractory erectile dysfunction: the latest advances.
National Journal of Andrology 2009;15(11):1035-1038
In recent years, more and more attention has been drawn to the role of phosphodiesterase 5 (PDE5) in penile erection. The cyclic nucleotide (cGMP) signaling pathway mediates the smooth-muscle relaxing effect of nitric oxide necessary for normal erectile function. Down-regulation of this pathway is the pathological pivot of many forms of erectile dysfunction (ED) and leads to the development of some chronic diseases. Therapeutic outcomes have shown that vardenafil is effective and safe in the treatment of ED associated with dyslipidemia, hypertension, depression, diabetes, radical retropubic prostatectomy, spinal cord injury, sildenafil failure, renal transplantation, chronic prostatitis and that accompanied by premature ejaculation. Vardenafil provides a reasonable therapeutic alternative for these refractory ED patients. In addition, vardenafil can prolong erectile duration of ED patients.
Cyclic Nucleotide Phosphodiesterases, Type 5
;
therapeutic use
;
Erectile Dysfunction
;
drug therapy
;
Humans
;
Imidazoles
;
therapeutic use
;
Male
;
Phosphodiesterase Inhibitors
;
therapeutic use
;
Piperazines
;
therapeutic use
;
Sulfones
;
therapeutic use
;
Triazines
;
therapeutic use
;
Vardenafil Dihydrochloride
;
Vasodilator Agents
;
therapeutic use
8.A clinical study of sertraline and vardenafil in the treatment of premature ejaculation complicated by erectile dysfunction.
Xiang-Zhou SUN ; Chun-Hua DENG ; Yu-Ping DAI
National Journal of Andrology 2007;13(7):610-612
OBJECTIVETo evaluate the efficacy and safety of sertraline and vardenafil in the treatment of patients with concomitant erectile dysfunction (ED) and premature ejaculation (PE).
METHODSSixty patients with concomitant ED and PE received at our clinic of andrology were randomly divided into a vardenafil group and a sertraline group. The vardenafil group received flexible doses of vardenafil from 10 mg to 20 mg and the sertraline group 50 mg daily, both for 2 months. The differences in IIEF-5 before and after the treatment were recorded and compared, and the results of ED treatment evaluated. Intravaginal ejaculatory latency time (IELT) was recorded to evaluate the outcome of PE treatment.
RESULTSIn the vardenafil group, 24 patients had their ED improved and the efficacy rate was 80%, as compared with 27% in the sertraline group. There was significant difference between the two groups (P < 0.05). Twenty patients had their PE improved in vardenafil group, with an efficacy rate of 67% as compared with 40% in the sertraline group. The difference was significant between the two groups (P < 0.05). In both of the two groups, a significantly higher rate of PE improvement was found in patients with improved ED than in those without. Only mild side effects were recorded, and none withdrew from the treatment.
CONCLUSIONTo patients with concomitant ED and PE, the key to the treatment is to improve their erectile function, and for this purpose, vardenafil works better than sertraline.
Adult ; Ejaculation ; drug effects ; Erectile Dysfunction ; drug therapy ; Humans ; Imidazoles ; therapeutic use ; Male ; Middle Aged ; Phosphodiesterase Inhibitors ; therapeutic use ; Piperazines ; therapeutic use ; Serotonin Uptake Inhibitors ; therapeutic use ; Sertraline ; therapeutic use ; Sulfones ; therapeutic use ; Treatment Outcome ; Triazines ; therapeutic use ; Vardenafil Dihydrochloride
9.Treatment of erectile dysfunction after radical retropubic prostatectomy with PDE5 inhibitor.
National Journal of Andrology 2005;11(9):708-712
The rate of erectile dysfunction after radical retropubic prostatectomy is from 10% to 100%. The prevalence of erectile dysfunction after nerve-sparing radical prostatectomy is more than one third. In the patients who had undergone bilateral NS, 72% responded to sildenafil, 71.7% and 59.7% responded to 20 mg and 10 mg of vardenafil respectively. For all randomized patients who received tadalafil, the mean percentage of successful penetration attempts was 54% and the mean percentage of successful intercourse attempts was 41%. For the subgroup with evidence of postoperative tumescence these values were 69% and 52%, respectively. No head-to-head trials have been performed with sildenafil, vardenafil and tadalafil in treatment of erectile dysfunction after radical prostatectomy.
Carbolines
;
therapeutic use
;
Erectile Dysfunction
;
drug therapy
;
etiology
;
Humans
;
Imidazoles
;
therapeutic use
;
Male
;
Phosphodiesterase Inhibitors
;
therapeutic use
;
Piperazines
;
therapeutic use
;
Prostatectomy
;
adverse effects
;
Purines
;
therapeutic use
;
Sildenafil Citrate
;
Sulfones
;
therapeutic use
;
Tadalafil
;
Triazines
;
therapeutic use
;
Vardenafil Dihydrochloride
10.Progress in the clinical use of anti-arrhythmic drugs (I).
Chinese Journal of Pediatrics 2003;41(10):735-737
Amiodarone
;
therapeutic use
;
Anti-Arrhythmia Agents
;
classification
;
therapeutic use
;
Arrhythmias, Cardiac
;
drug therapy
;
Child
;
Clinical Trials as Topic
;
Humans
;
Hydantoins
;
Imidazoles
;
therapeutic use
;
Imidazolidines
;
Phenethylamines
;
therapeutic use
;
Piperazines
;
therapeutic use
;
Sulfonamides
;
therapeutic use